Calprotectin as a companion biomarker for colorectal cancer: A lesson from microscopic bowel inflammation
International Journal of Rheumatic Diseases · 2023
DOI: 10.1111/1756-185x.14677 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Rheumatic Diseases, 2023. Verfasst von Chi-Hsien Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Show Chwan Memorial Hospital, Changhua, Taiwan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: Show Chwan Memorial Hospital.
Abstract (Originalsprache)
Dear Editor, We read with great interest the report by Campos et al regarding fecal calprotectin as a biomarker for the evaluation of microscopic bowel inflammation in patients with spondyloarthritis (SpA).1,2 In light of this study, we would like to describe our finding based on pharmacogenetics analysis, to propose another potential of calprotectin as a companion biomarker for patients with colorectal cancer. Calprotectin (also known as S100A8/A9) acts as a releasing factor from activated phagocytes such as synovial monocytes and granulocytes to promote inflammatory response through Tolllike receptor 4 (TLR4) signaling pathway.3 Calprotectin comprises 2 subunits, S100A8 and S100A9, which serve as the active and regulatory subunit, respectively. We found that high expression level of S100A9 serves as an indicator for unfavorable overall survival in patients with rectum adenocarcinoma (Figure 1). To investigate whether S100A9 could be a companion biomarker for the treatment of colorectal cancer, we employed pharmacogenetics analysis using Genomics of Drug Sensitivity in Cancer (GDSC) repository, to examine the association between S100A9 expression levels in 40 colorectal carcinoma cell lines and drug response to 443 drugs. As shown in Figure 2A, 39 out of 443 drugs were identified to feature significant association. A negative correlation between S100A9 expression levels and drug sensitivity of tavozanib was noted (Figure 2B). This finding implies high S100A9 expression could be an indicator of drug susceptibility to tavozanib. Importantly, tavozanib acting as selective inhibitor of vascular endothelial growth factor receptor1, 2 and 3 has undergone a phase II trial in 2016.4 In summary, we provide evidence that calprotectin subunit S100A9 could act as a companion biomarker in response to tavozanib treatment in association with clinical study by Campos et al. Calprotectin not only serves as a critical biomarker for the evaluation of microscopic bowel inflammation in patients with SpA, but also could provide an opportunity for the development of a companion biomarker for colorectal cancer treatment. Further investigation into the mechanisms underlying the role of calprotectin in tavozanib sensitivity is mandatory. In addition, rigorous clinical trials are warranted to confirm the pharmacogenetics findings before conclusions can be drawn.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Show Chwan Memorial Hospital, Changhua, Taiwan.
- Department of Emergency Medicine, Sinying Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
- Department of Physical Medicine and Rehabilitation, Pingtung Veterans General Hospital, Pingtung, Taiwan.
- Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan.
- College of Nursing, Central Taiwan University of Science and Technology, Taichung City, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Förderung
- Show Chwan Memorial Hospital
Zitieren
APA
Chang, C. H., Lee, W. K., Chou, M. C., Ho, H. W., & Lin, H. Y. (2023). Calprotectin as a companion biomarker for colorectal cancer: A lesson from microscopic bowel inflammation. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.14677
Vancouver
Chang CH, Lee WK, Chou MC, Ho HW, Lin HY. Calprotectin as a companion biomarker for colorectal cancer: A lesson from microscopic bowel inflammation. International Journal of Rheumatic Diseases. 2023. doi:10.1111/1756-185x.14677
BibTeX
@article{Chang2023,
author = {Chang, Chi-Hsien and Lee, Wei-Kai and Chou, Mei-Chia and Ho, Hui-Wen and Lin, Hung-Yu},
title = {Calprotectin as a companion biomarker for colorectal cancer: A lesson from microscopic bowel inflammation},
journal = {International Journal of Rheumatic Diseases},
year = {2023},
doi = {10.1111/1756-185x.14677}
}
EUVIMED